Dermatology Studies - enrolling now

  • Decks and Patios icon

    Topical Agents for Hidradenitis Suppurativa

    Phase 3, randomized, double-blind, controlled, efficacy, and safety study of a topical cream in participants age 12 and up with mild to moderate Hidradenitis Suppurativa

  • Outdoor Spaces icon

    Oral Agents for Hidradenitis Suppurativa

    Phase 3, randomized, double-blind, efficacy and safety study of an oral agent in adults with moderate to severe Hidradenitis Suppurativa (and Long-Term Extension Study)

  • Injectable Agents for Hidradenitis Suppurativa

    A Phase 3 randomized, double-blind, controlled, efficacy and safety study of a subcutaneous injection in adults with moderate to severe Hidradenitis Suppurativa

    Phase 2b, randomized, double-blind, controlled, efficacy, and safety study of a subcutaneous injection in adults with moderate to severe Hidradenitis Suppurativa

  • Green Building icon

    Teen Hidradenitis Suppurativa

    Phase 3, open-label, single-arm study to evaluate pharmacokinetics and safety of a subcutaneous injection in adolescents, ages 12-17, with moderate to severe Hidradenitis Suppurativa

Our
Team

  • SYP headshot

    Dr. So Yeon Paek (MD)

    Principal Investigator

  • XF headshot

    Xochitl Flores (CRC)

    Study Coordinator/Regulatory Affairs

  • Quinette Haynes (CRC)

    Study Coordinator/Regulatory Affairs

  • Claire Jung (PA-C)

    Sub-Investigator